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of pigmentation-related genes3 with a median on target fold
coverage of > 1000 9. A missense substitution at codon 203
in MAP2K1 (c.607G>A, p.E203K) was identified within both
melanomas (medial left thigh and left lateral foot) and also
within the background NS-type CMN. Allele loads were 7% in
the SSMM, 2% in the LMM and 1% in the NS-type CMN. A
second variant in MAP2K1 (c.308T>A, p.l103N) was also seen
in the SSMM (7% allele load), but undetectable in the other
melanoma and NS-type CMN. Targeted sequencing specifically
excluded HRAS, NRAS and BRAF mutations in the NS-type CMN
and melanomas.
NS-type CMN have previously been associated with
specific mosaic variants in NRAS.1,2,4 Our patient differs
phenotypically from prior cases and has many small, dark
naevi on the skin of the affected limb with no apparent
cafe-au-lait pigmentation. These naevi were not present at
birth, and continue to develop. NS-type CMN are a
clinically heterogeneous entity, and our finding of a
postzygotic mutation in MAP2K1 adds to known existing
drivers such as NRAS.4 The MAP2K1 E203K variant lies
within the protein kinase domain of the MAP2K1 protein.
This results in a gain of function at the protein level;
E203K-mutated melanoma cell lines demonstrate constitu-
tive phosphorylation of extracellular signal-regulated
kinase, a downstream kinase in the Ras signalling path-
way.5 Importantly, similar mutations in the germline give
rise to cardiofaciocutaneous syndrome, which has been
associated with increased numbers of melanocytic naevi,
adding support for the pathogenicity of this variant.6 Fur-
thermore, MAP2K1 mutations have been found in up to
6% of cases in a series of melanoma.5 Mosaic MAP2K1
variants have recently been described as a cause of arteri-
ovenous malformations,3 but not previously in melanocy-
tic lesions. Taken together, our findings suggest that our
patient’s NS-type CMN is driven by a postzygotic muta-
tion in MAP2K1, predisposing to development of mela-
noma within the lesion. It is of interest that a second
pathogenic variant in MAP2K1 (p.l103N) was detected in
one melanoma at an identical allele load. It hints at the
possibility that biallelic mutations in MAP2K1 are impor-
tant to initiate melanoma formation in this birthmark. It
would be of interest to determine if loss of heterozygos-
ity of MAP2K1 has occurred specifically in melanoma cells
in this patient’s remaining melanomas; however, technical
issues relating to working with paraffin-embedded tissue
prevent this from being demonstrated unequivocally. Our
findings highlight the clinical and genetic heterogeneity
in NS-type CMN. These data add evidence to the central
role of Ras signalling in CMN and melanoma develop-
ment, and the need for long-term follow-up of such
patients.
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Partner bereavement and risk of chronic
urticaria, alopecia areata and vitiligo: cohort
studies in the UK and Denmark
DOI: 10.1111/bjd.19122
DEAR EDITOR, The pathogeneses of skin diseases are not fully
understood. Psychological stress has been proposed to be asso-
ciated with skin diseases, but the epidemiological evidence is
limited.1,2 We have recently reported the associations between
partner bereavement (an extreme life stressor) and psoriasis,
atopic eczema and melanoma.3,4 In this study, we further
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investigated whether partner bereavement was associated with
urticaria, alopecia areata or vitiligo.
We conducted two cohort studies using data from the UK
(1997–2017) and Denmark (1997–2016). To identify part-
ners, in the UK we used the Clinical Practice Research Data-
link, with a previously developed algorithm;3,4 in Denmark
we used data from the Civil Registration System, with an algo-
rithm developed by Statistics Denmark.3,4 Among eligible cou-
ples we defined bereaved people (exposed) if their partner
died, and matched each with up to 10 nonbereaved partners
on age, sex and county of residence within Denmark, or gen-
eral practice in the UK, on the bereavement date.
We followed participants from bereavement until the first
of: diagnosis of specific outcomes (urticaria, alopecia areata or
vitiligo), last data collection from primary care practice (UK),
transfer out of the practice by either member of the couple
(UK), emigration of either member of the couple (Denmark),
death, or the study end. We used stratified Cox regression to
estimate hazard ratios (HRs) with 95% confidence intervals
(CIs) for each outcome, adjusting for participants’ Charlson
Comorbidity Index (CCI).5 In the fully adjusted model, we
additionally adjusted for education duration (Denmark), Index
of Multiple Deprivation quintile (UK), body mass index (UK)
and lifestyle variables (UK).
As we hypothesized that the effect of bereavement
would be most pronounced in the short term, we further
examined the associations by time since bereavement (0–
30 days, 0–90 days, 0–365 days and 0–1095 days for
alopecia areata and vitiligo; and 0–182 days, 0–365 days
and 0–1095 days for chronic urticaria as its definition
required two codes recorded 6 weeks apart). We stratified
the main analysis by age, sex and risk of partner death
(deceased partner’s age-adjusted CCI score and presence of
terminal disease). We conducted analyses separately for the
UK and Denmark, and combined the main results (from
the adjusted models) in Stata/MP 151 (StataCorp, College
Station, TX, USA) and SAS 94 (SAS Institute Inc., Cary,
NC, USA), using the DerSimonian and Laird random-effects
model.
Overall median follow-up was 4 years in the UK and 6
years in Denmark. Overall pooled HRs (adjusted for partici-
pants’ CCI scores) for associations between partner bereave-
ment and chronic urticaria, alopecia areata and vitiligo were
095 (95% CI 085–107), 090 (95% CI 073–112) and
090 (95% CI 074–110), respectively. We found similar
results for chronic urticaria in analyses by time since bereave-
ment (Table 1). Event rates for alopecia areata and vitiligo
were low, specifically in early time periods. Similar results
were seen in fully adjusted models (data available on request).
For subgroup analyses, some evidence suggested that the HR
for vitiligo differed by sex (lower HR among men) in the UK.
No substantial differences were observed across other sub-
groups for other outcomes.
This study investigated associations between partner
bereavement and chronic urticaria, alopecia areata and viti-
ligo in population-based cohorts in settings with universal























Entire follow-up 269 875 386 2483 7 615 764 096 (084–109) 67 2 778 742 646 23 908 253 093 (072–120)
0–182 days b 78 004 b 713 353 031 (008–128) b 176 120 b 1 684 577 NA
0–365 days 20 150 221 214 1 376 313 088 (056–140) b 345 359 b 3 288 129 060 (014–250)
0–1095 days 85 388 765 846 3 542 326 093 (074–116) 10 947 459 148 8 840 820 064 (034–122)
Alopecia areata
Entire follow-up 49 901 811 525 8 087 071 081 (060–110) 48 2 793 638 417 24 175 497 100 (074–136)
0–30 days b 13 817 b 129 863 NA b 29 816 b 288 053 NA
0–90 days b 40 793 35 384 648 024 (003–174) b 88 713 b 856 229 NA
0–365 days 8 155 369 105 1 470 901 069 (034–142) b 347 651 b 3 333 059 NA
0–1095 days 26 401 742 247 3 779 874 091 (060–137) 16 953 497 129 8 957 716 120 (071–202)
Vitiligo
Entire follow-up 87 910 002 972 8 215 110 084 (067–105) 36 2 793 919 314 24 178 445 105 (074–149)
0–30 days b 13 925 b 131 873 063 (008–483) b 29 817 b 288 077 NA
0–90 days 5 41 110 39 390 610 132 (052–337) b 88 717 b 856 303 NA
0–365 days 23 156 584 177 1 493 648 130 (084–202) b 347 669 b 3 333 348 016 (002–115)
0–1095 days 54 404 936 449 3 838 367 118 (089–157) 8 953 555 128 8 958 460 059 (029–121)
HR, hazard ratio; CI, confidence interval; NA, not applicable. aAdjusted for Charlson Comorbidity Index scores. bIn accordance with the con-
fidentiality rules of the Clinical Practice Research Datalink/Danish registries, we have not presented results where numbers of events are less
than five.
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healthcare (UK and Denmark), using harmonized methodol-
ogy. Previous studies have been limited by small sample size,
difficulty in measuring stress, and potential misclassification
of adverse life events due to recall bias.6–8 We undertook
our study in two similar cohorts to enable replication, and
used partner bereavement as a proxy for acute severe stress,
with specific onset date. Limitations include a lack of infor-
mation on the level and duration of stress arising from
bereavement, individual responses to bereavement, social
support, potential misclassification of partnership status, pos-
sible delay between disease onset and diagnosis, overrepre-
sentation of severe cases in the Danish hospital setting, and
absence (Denmark) and missingness (UK) of body mass
index and lifestyle covariates. People with mild skin condi-
tions may be less likely to seek medical advice immediately
after bereavement, which may have led to underestimation
during short-term follow-up, and an overrepresentation of
the most severe skin diseases.
In conclusion, this large study showed no evidence of
associations between partner bereavement and chronic urti-
caria, alopecia areata or vitiligo. Despite a large study popula-
tion, precision was limited by low event rates for alopecia
areata and vitiligo, especially in early time periods. Details of
the methods, additional and sensitivity analyses, and discus-
sion of results, can be found via https://doi.org/10.17037/
pubs.04656104.
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High and discordant prevalences of clinical
and sonographic enthesitis in patients with
hidradenitis suppurativa
DOI: 10.1111/bjd.19135
DEAR EDITOR, The prevalence of spondyloarthritis (SpA)
reported among patients with hidradenitis suppurativa (HS)
ranges from 23% to 282%, depending on the diagnostic
method used.1 A key feature of SpA and one of the European
Spondyloarthropathy Study Group diagnostic criteria for this
group of diseases is enthesitis: inflammation at the insertion
of tendons, ligaments and capsules. However, pain at an
entheseal site is nonspecific and does not always indicate
inflammation. Objective assessment of the presence of enthesi-
tis can be done using ultrasound.2 Therefore, the aim of this
cross-sectional study was to investigate the prevalence of clini-
cal enthesitis among patients with HS and to correlate it with
sonographic enthesitis.
Patients were selected randomly prior to their routine visit
at the specialized HS outpatient clinic of a tertiary centre in
the Netherlands between October 2018 and February 2019.
The study was approved by the medical ethical committee of
the Erasmus University Medical Center (MEC-2018-158).
Patient characteristics were collected through the HiScreen
Registry (MEC-2016-426) and patient charts.
Clinical enthesitis, defined as pain elicited by local pressure
at the enthesis, was assessed bilaterally at eight entheseal
points (total 16 sites) according to the Spondyloarthritis
Research Consortium of Canada (SPARCC) criteria.3 Ultra-
sound examination was performed according to the Madrid
Sonographic Enthesitis Index at six bilateral entheses and
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